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http:WHAT THIS PAPER ADDS
The current study is one of the ﬁrst clinical analyses to examine the potential relationship between arterial
stiffness and serum ﬁbulin-1 in patients with atherosclerosis. The study suggests that a higher ﬁbulin-1 level is an
independent predictor of enhanced systolic wave reﬂection in patients with symptomatic peripheral arterial
disease. In addition, it was found that this extracellular matrix protein may be associated with low grade
inﬂammation in atherosclerosis. Therefore, ﬁbulin-1 could serve as a candidate marker for systemic vascular
damage.Background: Fibulin-1 (FBLN-1), a newly identiﬁed biomarker for vascular stiffness in type 2 diabetes, may
participate in the pathophysiological processes leading to progression of arterial stiffness in atherosclerosis. In
the present study, the relationship between FBLN-1 and arterial stiffness was examined in patients with
atherosclerosis and in healthy subjects.
Methods: Thirty-eight patients with peripheral arterial disease (PAD) (age 62.4  9.0 years), 38 patients with
coronary artery disease (CAD) (age 64.0  9.5 years), and 30 apparently healthy controls (age 61.1  6.4 years)
were studied. Serum FBLN-1, oxidized low density lipoprotein (oxLDL), resistin and plasminogen activator
inhibitor-1 (PAI-1) levels were measured using the enzyme linked immunosorbent assay method. The technique
of applanation tonometry was used for non-invasive pulse wave analysis and pulse wave velocity assessments.
Results: The levels of FBLN-1 (PAD ¼ 9.4 [4.9e17.8] vs. CAD ¼ 7.1 [4.8e11.8] vs. controls ¼ 5.6 [4.1e8.4] mg/
mL; p ¼ .005), carotid-femoral pulse wave velocity (cf-PWV) (9.8  2.2 vs. 9.5  2.2 vs. 8.3  2.2 m/s; p ¼ .023)
and the heart rate corrected augmentation index (AIx@75) (29.4  7.2 vs. 19.2  7.2 vs. 15.4  7.1%; p < .001),
differed among the three groups. A correlation between FBLN-1 and AIx@75 was observed only in patients with
PAD (rho ¼ 0.37, p ¼ .021). The relationship retained statistical signiﬁcance in a multiple regression model after
adjustment for potential confounders.
Conclusions: An independent association was demonstrated between serum FBLN-1 and AIx@75 in the PAD
group. Thus, the ﬁndings suggest that FBLN-1 may play a role in arterial stiffening in patients with atherosclerosis.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Arterial stiffness is one of the earliest detectable manifes-
tations of adverse structural and functional changes in the
vessel wall.1 It is positively associated with age, systolic
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//dx.doi.org/10.1016/j.ejvs.2015.09.004arterial disease.2e5 Reduction in the buffering capacity of
the large arteries leads to increased systolic and pulse
pressure, promotes left ventricular hypertrophy, impairs
coronary artery perfusion, and predisposes the peripheral
microcirculation to increased pulsatile energy.6,7 Arterial
stiffening is recognized as an independent predictor of
cardiovascular and all cause mortality in patients with
atherosclerosis, and its assessment is becoming more
widely used in daily clinical practice to identify high risk
patients who may beneﬁt from more aggressive cardio-
vascular disease risk management.8e10
A considerable amount of effort has been put into ﬁnding
and evaluating new biochemical cardiovascular risk
markers. Fibulin-1 (FBLN-1), an extracellular matrix
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ment membranes, is one of the few extracellular matrix
proteins normally present in high concentrations in
blood.11,12 It is expressed, among other tissues, in the car-
diac valves and in the blood vessel wall, and seems to be
crucial in embryonic development.13e15 Mice lacking FBLN1
expression die perinatally because of massive bleeding and
impaired development of alveolar and glomerular base-
ment membranes.16 As prominent deposition of FBLN-1 has
been found in human coronary artery atherosclerotic le-
sions, the protein is believed to participate in the patho-
physiological processes leading to the progression and
thrombotic complications of atherosclerosis.17 Further-
more, a recent study showed that FBLN-1 correlates with
carotid-femoral pulse wave velocity (cf-PWV), a measure of
arterial stiffness, and predicts mortality in patients with
type 2 diabetes.18 The authors suggested that it could play a
part in arterial extracellular matrix alterations and thus in
the stiffening of the vessel wall in these patients. However,
diabetes is a well known risk factor for atherosclerosis and
the role of FBLN-1 in the pathophysiology of different
atherosclerotic cardiovascular diseases still needs to be
elucidated. In non-diabetic subjects, no correlation has
been found between cf-PWV and FBLN-1. Still, several
biochemical cardiovascular risk markers, including non-high
density lipoprotein cholesterol, apolipoprotein B, and high
sensitivity troponin T, seem to correlate with this emerging
biomarker.18,19 The objective of the present study was to
evaluate the association between serum FBLN-1, arterial
stiffness, and central hemodynamics in peripheral arterial
disease (PAD) patients, coronary artery disease (CAD) pa-
tients, and clinically healthy controls.
METHODS
Study population
Thirty-eight patients with symptomatic PAD and 38 patients
with symptomatic CAD were prospectively included in the
study. The patients were recruited from the Departments of
Vascular Surgery and Cardiology, University of Tartu,
Estonia. They were all male with angiographically proven
PAD or CAD. The exclusion criteria for both groups were any
comorbid acute or chronic inﬂammatory disease, diabetes
mellitus, myocardial infarction, cerebrovascular events or
revascularization operation during the preceding 6 months,
unstable angina, cardiac arrhythmias, clinically signiﬁcant
heart failure or valvular disease, reduced kidney function
(estimated glomerular ﬁltration rate [eGFR] <60 mL/min/
1.73 m2), presence of cancer, or endocrine pathology. In the
PAD group, six (16%) subjects with CAD as the comorbidity
were included in the analysis.
Thirty age and gender matched clinically healthy controls
were identiﬁed through local family physicians in the same
geographical area. In the control group, the following
exclusion criteria were applied: any comorbid acute or
chronic inﬂammatory disease, coronary artery disease, ce-
rebral or peripheral atherosclerotic disease, diabetes mel-
litus, cardiac arrhythmias, clinically signiﬁcant heart failureor valvular disease, reduced kidney function (eGFR<60 mL/
min/1.73 m2), presence of cancer, infectious disease or
endocrine pathology, or regular use of any medication.
Study protocol
All subjects completed a lifestyle and medical history
questionnaire. Peripheral venous blood samples were
collected after an overnight fast and abstinence from to-
bacco, alcohol, tea, or coffee. Thereafter, height and weight
were assessed and body mass index (BMI) was calculated.
Brachial blood pressure, pulse wave analysis, cf-PWV, and
carotid radial pulse wave velocity (cr-PWV) were assessed in
a quiet, temperature controlled room with the patients
resting in a supine position for at least 10 minutes. All he-
modynamic measurements were taken in duplicate and
averaged. The study protocol was approved by the ethics
committee of the University of Tartu, and all subjects gave
their written informed consent.
Arterial stiffness and central hemodynamics
measurements
Aortic augmentation index corrected for a heart rate of
75 bpm (AIx@75) and central hemodynamic parameters
were evaluated non-invasively with the commercially
available SphygmoCor apparatus (AtCor Medical, Sydney,
Australia).20 In brief, 15 sequential high quality radial
waveforms were recorded at the patient’s left wrist using a
high ﬁdelity micromanometer (SPT-301B; Millar In-
struments, Houston, TX), after which a validated generalized
transfer function for calculation of the central aortic pres-
sure waveform was used.21,22 The augmentation index (%)
was deﬁned as the difference between the second and ﬁrst
systolic peaks of the central arterial waveform, expressed as
a percentage of the central pulse pressure.23 Higher values
of AIx@75 may indicate increased arterial wave reﬂection
and a reduction in the reservoir function of the aorta.24
Pulse wave velocity is a regional functional measurement
of arterial stiffness over a certain arterial length.1 The cf-
PWV and cr-PWV were calculated from pulse transit time
using electrocardiogram gated carotid and femoral or radial
artery waveform recordings over a known distance
(SphygmoCor; AtCor Medical, Sydney, Australia).20 For
calculation of cf-PWV, the distance from suprasternal notch
over umbilicus to the femoral artery minus carotid arterial
length was used. Cf-PWV is a direct measure of aortic
stiffness and considered to be the “gold standard” of arte-
rial stiffness measurements.23 Pulse pressure ampliﬁcation
(PPP/CPP) was expressed as the percentage ratio of radial
pulse pressure (PPr) to aortic pulse pressure (PPa), ac-
cording to the formula: PPP/CPP ¼ PPr : PPa  100 (%).
Biochemical analysis
Peripheral venous blood samples were collected and
centrifuged at room temperature. The serum was distrib-
uted between Eppendorf tubes and stored at 70 C until
analysis. Serum FBLN-1 and oxidized low density lipoprotein
(oxLDL) levels were measured using an enzyme linked
Table 1. Baseline characteristics of the study groups.
Variable PAD patients CAD patients Controls p-value
(n ¼ 38) (n ¼ 38) (n ¼ 30)
Age, years 62.4  9.0 64.0  9.5 61.1  6.4 .36
BMI, kg/m2 25.5  3.3b 27.5  3.2 26.0  3.3 .02
Height, m 172.0  5.8a,b 175.8  6.6 179.2  6.5 <.001
Peripheral SBP, mmHg 144  18a,b 135  15 127.0  13 <.001
Peripheral DBP, mmHg 81  9 78  8 77  7 .20
Central SBP, mmHg 135  17a,b 124  13 118  13 .004
Central DBP, mmHg 81  10 79  7 78  7 .25
MAP, mmHg 103  12a 97  9 95  10 .004
Heart rate, bpm 64.6  11.3a 61.4  7.8 57.6  7.3 .008
PPP/CPP 1.19  0.9a,b 1.28  0.1 1.28  0.1 .001
WBC count, 109/L 7.8  1.9a,b 6.3  1.6a 4.9  0.6 <.001
PLT count, 109/L 244  59a 219  48 213  31 .03
Total cholesterol, mmol/L 5.4  1.2 5.2  1.1 5.5  1.0 .41
HDL cholesterol, mmol/L 1.1 (1.0e1.4)a,b 1.5 (1.1 1.7) 1.5 (1.3 1.8) <.001
LDL cholesterol, mmol/L 3.6  1.1 3.4  1.1 3.6  0.9 .54
Triglycerides, mmol/L 1.6 (0.9e2.2) 1.2 (0.8e1.7) 0.9 (0.7e1.4) .01
Glucose, mmol/L 5.4  0.8b 5.8  0.6 5.8  0.5 .02
eGFR, mL/min/1,73m2 91.1  18.4 82.8  14.4 83.4  11.6 .04
hsCRP, mg/L 4.4 (1.1 7.6)a,b 1.3 (0.8e2.6) 1.1 (0.7e2.0) <.001
oxLDL, U/L 67.5 (53.4e85.6) 61.0 (50.3 81.8) 66.3 (53.5 84.4) .63
PAI-1, ng/mL 28.0  9.3 26.4  8.7 27.3  6.6 .73
Resistin, ng/mL 3.5 (2.8e4.5) 3.7 (2.8e4.9)a 2.8 (2.4e3.4) .25
Fibulin-1, mg/mL 9.4 (4.9e17.8)a 7.1 (4.8e11.8) 5.6 (4.1 8.4) .005
AIx@75, % 29.4  7.2a,b 19.2  7.2 15.4  7.1 <.001
cf-PWV, m/sc 9.8  2.2a 9.5  2.2 8.3  2.2 .023
cr-PWV, m/sc 9.3  1.2 9.5  1.1a 8.7  1.2 .024
Current smoking, n (%) 28 (72)a,b 8 (21) 3 (10) <.001
Medication, n (%)
ACE inhibitors 9 (23)a 13 (34)a 0 (0) <.001
Angiotensin receptor blockers 6 (15) 6 (16) 0 (0) .04
Calcium channel blockers 6 (15)b 14 (37)a 0 (0) <.001
Beta blockers 10 (26)a,b 27 (71)a 0 (0) <.001
Diuretics 3 (8) 4 (11) 0 (0) .20
Pentoxyfylline 13 (33)a,b 0 (0) 0 (0) <.001
Naftidrofuryl 8 (21)a,b 0 (0) 0 (0) <.001
Antiplatelets 13 (33)a,b 26 (68)a 0 (0) <.001
Statins 7 (18)a,b 20 (53)a 0 (0) <.001
The values are represented as means (standard deviation), medians (interquartile range), or prevalence (%). PAD ¼ peripheral arterial
disease; CAD ¼ coronary artery disease; BMI ¼ body mass index; SBP ¼ systolic blood pressure; DBP ¼ diastolic blood pressure;
MAP ¼ mean arterial pressure; PPP/CPP ¼ pulse pressure ampliﬁcation; WBC ¼ white blood cell count; PLT count ¼ platelet count;
HDL ¼ high density lipoprotein; LDL ¼ low density lipoprotein; eGFR ¼ estimated glomerular ﬁltration rate; hsCRP ¼ high sensitivity C-
reactive protein; PAI-1 ¼ plasminogen activator inhibitor-1; AIx@75 ¼ augmentation index adjusted to a heart rate of 75 beats per
minute; cf-PWV¼ carotid-femoral pulse wave velocity; cr-PWV¼ carotid radial pulse wave velocity; ACE¼ angiotensin converting enzyme.
a <0.05 vs. control group.
b <0.05 vs. CAD group.
c cf-PWV and cr-PWV have been adjusted for MAP.
78 K. Paapstel et al.immunosorbent assay (Human Fibulin-1 Kit, Cusabio
Biotech Co., Ltd; Merdcodia Oxidized LDL ELISA, Uppsala,
Sweden). The levels of serum resistin and plasminogen
activator inhibitor-1 (PAI-1) were determined using The
Evidence Investigator (Metabolic Syndrome Array-1, Randox
Laboratories, Crumlin, UK). The serum levels of glucose,
total cholesterol, low density lipoprotein cholesterol (LDL-
C), high density lipoprotein cholesterol (HDL-C), tri-
glycerides, white blood cell (WBC) count, platelet (PLT)
count, high sensitivity C-reactive protein (hsCRP), and esti-
mated glomerular ﬁltration rate were measured in the localclinical laboratory with automated analyzers using standard
laboratory methods.Statistical analysis
All statistical analyses were performed with the SPSS soft-
ware for Windows, version 22.0. Continuous variables are
expressed as mean  standard deviation or as median and
interquartile ranges. Categorical variables are expressed in
percentages. The normality of the distribution of continuous
variables was assessed using the Shapiro-Wilk test, and the
Table 2. Multiple regression model for PAD group with AIx@75 as
the dependent variable.
Variable Regression coefﬁcient Standard error p-value
FBLN-1 0.477 0.117 <.001
MAP 0.222 0.069 .003
Height 0.298 0.140 .041
R2 ¼ 0.454, p < .001. PAD ¼ peripheral arterial disease;
AIx@75 ¼ augmentation index adjusted to a heart rate of 75
beats per minute; FBLN-1 ¼ ﬁbulin-1; MAP ¼ mean arterial
pressure.
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transformation. Analysis of covariance was used to adjust
cf-PWV and cr-PWV for mean arterial pressure (MAP). One
way analysis of variance was employed for comparing the
mean values of normally distributed continuous variables
among the groups, and post hoc analysis was performed by
the Scheffé test to check for intergroup differences. A
Kruskal-Wallis test was conducted to determine differences
between the median values of non-normally distributed
variables among the groups and pairwise comparisons were
performed using Dunn’s procedure with a Bonferroni
correction for multiple comparisons. Pearson’s correlation
coefﬁcient and Spearman’s rank correlation were used to
measure the strength of the relationship between the
continuous variables, and multivariate analysis was applied
to investigate the independent determinants of FBLN-1. The
variables entered into the model were drawn from univar-
iate analysis, and from relevant published observations.
Multivariate analyses were performed using a stepwise
(forward followed by backward) multiple regression. Sta-
tistical signiﬁcance was deﬁned as p < .05. For the
dichotomous measures, the Fisher-Freeman-Halton test was
performed to compare the groups for each variable. The
results were corrected for multiple testing using the Bon-
ferroni correction. All statistical tests were checked for vi-
olations of assumptions.
RESULTS
Characteristics of the study population
The baseline characteristics of the study groups are pre-
sented in Table 1. There were no signiﬁcant differences in
mean age, peripheral and central diastolic pressure, total
and LDL-C, oxLDL, PAI-1, or resistin levels between theFigure 1. Scatterplot showing correlation between heart rate
corrected augmentation index (AIx@75) and serum ﬁbulin-1 for
the peripheral arterial disease patients (rho ¼ 0.37, p ¼ .021).investigated groups. The patients with PAD differed signiﬁ-
cantly from both the CAD and control subjects with respect
to height, peripheral and central systolic pressure, pulse
pressure ampliﬁcation, WBC count, HDL-C, hsCRP, AIx@75,
and current smoking status. Differences in MAP, heart rate,
cf-PWV, PLT, and FBLN-1 levels emerged only from com-
parison with the controls. The CAD patients had signiﬁcantly
higher BMI and glucose levels than the PAD patients and
higher cr-PWV, WBC count, and resistin than the controls.Association between arterial stiffness and biochemical
markers
In univariate analysis, FBLN-1 correlated positively with
AIx@75 for the PAD patients (rho ¼ 0.37, p ¼ .021; Fig. 1),
but not for the CAD patients (rho ¼ 0.02, p ¼ .91) or for
the control group (r ¼ 0.01, p ¼ .95). In multivariate
analysis with AIx@75 as the dependent variable, FBLN-1,
MAP, and height were signiﬁcant independent variables in
the PAD group (R2 ¼ 0.45; p < .001; Table 2). There was no
correlation between serum FBLN-1 and cf-PWV in any of the
studied groups (data not shown).
In univariate analysis, FBLN-1 was correlated with resistin
(rho ¼ 0.40; p ¼ .013),WBC (rho ¼ 0.39; p ¼ .018), and PLT
(rho ¼ 0.38; p ¼ .019) for the PAD group, while in multi-
variate analysis with FBLN-1 as the dependent variable,
resistin and AIx@75 remained signiﬁcant determinants for
these patients (R2 ¼ 0.31, p ¼ .002; Table 3). In the CAD
group, WBC (rho ¼ 0.36, p ¼ .035) and height
(rho ¼ 0.41, p ¼ .012) correlated univariately with FBLN-1Table 3. Multiple regression model for PAD and CAD patients with








AIx@75 0.495 0.160 .004





WBC 0.875 0.328 .013
Height 0.210 0.081 .015
Statin treatment 1.933 1.095 .089
PAD ¼ peripheral arterial disease; CAD ¼ coronary artery disease;
FBLN-1 ¼ ﬁbulin-1; AIx@75 ¼ augmentation index adjusted to a
heart rate of 75 beats per minute; WBC ¼ white blood cell count.
a R2 ¼ 0.314, p ¼ .002.
b R2 ¼ 0.332, p ¼ .002.
80 K. Paapstel et al.and remained signiﬁcant in multivariate analysis (R2 ¼ 0.33,
p ¼ .002; Table 3), while for the control subjects, only PAI-1
was found to correlate with FBLN-1 (r ¼ 0.39; p ¼ .048).
However, this difference did not reach statistical signiﬁcance
in multivariate analysis (data not shown).DISCUSSION
To the authors’ knowledge, this is the ﬁrst study to
demonstrate an independent association between serum
FBLN-1 concentration and AIx@75 in subjects with PAD.
Furthermore, signiﬁcantly higher FBLN-1 and AIx@75 levels
were also found in the PAD group compared with the
controls. This ﬁnding suggests that the correlation between
FBLN-1 and AIx@75, an established surrogate marker of
pulse wave reﬂection and arterial stiffness, becomes
apparent in more distal diffuse atherosclerosis commonly
seen in patients with PAD. Moreover, PAD patients tend to
be less likely to receive optimal medical management than
patients with CAD.25 Previous studies in subjects with dia-
betes and chronic kidney disease showed that FBLN-1
correlated with cf-PWV and un-adjusted augmentation in-
dex respectively, although the latter relationship did not
retain statistical signiﬁcance in multivariate analysis.12,18
Interestingly, both of these diseases are strongly associ-
ated with the diffuse atherosclerotic phenotype and
increased arterial stiffness.26,27
A signiﬁcant correlation between serum FBLN-1 and
several biochemical markers of inﬂammation was also
observed. Serum resistin was an independent determinant
of FBLN-1 concentration in PAD patients. Increased serum
levels of this adipokine have previously been associated with
insulin resistance and atherosclerosis.28,29 Elevated resistin
levels are also associated with coronary artery disease and
the risk of cardiovascular death.30 Interestingly, in the pre-
sent study, no signiﬁcant differences were found between
groups in the concentrations of this pro-inﬂammatory adi-
pokine, implying that the correlation between FBLN-1 and
resistin for the PAD group may have appeared because of
more extensive vascular injury and increased FBLN-1 levels in
these patients compared with the CAD and control groups.
A high WBC count may reﬂect a chronic inﬂammatory
state and may affect vascular function in individuals with
low cardiovascular risk.31 Leukocytes play an important role
in the genesis of atherosclerosis as they represent the
predominant cell population involved in inﬂammation.32 In
the current study, a higher WBC count was observed in the
PAD and CAD groups, compared with the healthy controls.
Univariate correlation was found between WBC count and
serum FBLN-1 in the PAD and CAD patients, and it retained
statistical signiﬁcance in multivariate analysis in the CAD
group. This could suggest that the systemic inﬂammatory
state, common in atherosclerosis, has an effect on FBLN-1
serum levels. Whether or not the same correlation is
observed in non-atherosclerotic patients with high WBC
count remains to be elucidated.
A higher PLT count also was found in the PAD group
compared with the healthy controls. Increased PLTaggregation and activation have previously been observed in
patients with PAD.33 Furthermore, thrombotic events like
myocardial infarction and stroke are common causes of
morbidity andmortality in these patients.34 The potential role
of FBLN-1 in hemostasis and thrombosis has been addressed
as well. Several studies indicate that FBLN-1 can mediate PLT
adhesion by binding ﬁbrinogen, and is able to incorporate into
ﬁbrin clots, and accumulates in human atherosclerotic le-
sions.17 In accordancewith the role of FBLN-1 in PLT adhesion,
a correlation between FBLN-1 and PLT count in the PAD group
was found in the present study. Furthermore, PAI-1, an
important protein in ﬁbrinolysis as well as in tissue remod-
eling, correlatedwith FBLN-1 in the control group.35 Although
interesting, the exact mechanisms behind these ﬁndings
cannot be explained within the scope of the present study.
The present results seem to agree with several previous
investigations that have proposed FBLN-1 as a potential
cardiovascular risk marker. In addition to its probable role in
hemostasis and thrombosis, the present study suggests that
higher FBLN-1 levels may be related to enhanced central
aortic pressure in individuals with symptomatic PAD and,
hence, may have additional value in the assessment of
vascular function in these patients. However, larger studies
are needed to determine potential relationships between
FBLN-1 and arterial stiffness among patients with CAD.
The present study has several limitations. First, only male
participants were chosen to avoid the possible confounding
effects of estrogen. Therefore, the present ﬁndings cannot
be fully extrapolated to women and younger subjects.
Second, for ethical reasons, patients could not be with-
drawn from their medications to exclude any potential ef-
fects on hemodynamic parameters and levels of
biochemical markers. Also, as smokers were included in this
study, the long-term health consequences of smoking
cannot be ruled out. Third, it is acknowledged that the
number of participants in the study was relatively small and
larger studies are needed to conﬁrm or disprove the results.
Fourth, various stenotic arterial segments may have led to a
considerable underestimation of PWV, particularly in sub-
jects with PAD. Finally, as the design of the study is cross
sectional, it was not possible to establish causality.
In conclusion, an independent relationship has been
detected between serum FBLN-1 and aortic augmentation
index in patients with PAD. The ﬁndings also suggest that
this extracellular matrix protein may be associated with low
grade inﬂammation in atherosclerosis. Consequently, FBLN-
1 could serve as a candidate marker for systemic vascular
damage. However, future studies are needed to determine
the exact role of this protein in the circulatory system.CONFLICT OF INTEREST
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Multiple Cervical Artery Aneurysms with Congenital Scoliosis
S. Zhang, Y.-H. Zheng *
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, ChinaA 47 year old man with congenital scoliosis was admitted complaining of dizziness and progressively enlarging bilateral
neck swellings over 3 years. The patient had widely spaced eyes and bilateral pulsatile neck masses. Computed tomographic
angiography revealed that the bilateral vertebral, carotid, and basilar arteries were distorted by multiple fusiform aneu-
rysms, with the extracranial internal carotid artery aneurysms (ICAs) measuring (length  transverse diameter) 4.2  3.0 cm
on the left and 7.2  4.3 cm on the right. The patient was diagnosed with LoeyseDietz syndrome with TGFBR2 mutation.ier Ltd. All rights reserved.
